Biostate® Human Coagulation Factor VIII (FVIII) and Human Von Willebrand Factor (VWF) Complex, Powder for Injection

Total Page:16

File Type:pdf, Size:1020Kb

Biostate® Human Coagulation Factor VIII (FVIII) and Human Von Willebrand Factor (VWF) Complex, Powder for Injection Biostate® Human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF) complex, powder for injection. Consumer Medicine Information What is in this leaflet are essential for normal blood Before you are given clotting. ® This leaflet answers some Biostate ® common questions about Biostate is used in patients Tell your doctor if you: Biostate®. It does not contain with von Willebrand Disease (VWD), a bleeding disorder complete information about have allergies to any ® resulting from low levels of Biostate . medicines VWF or abnormal VWF. It does not take the place of Individuals with VWD tend to are taking or using any talking to your doctor. take longer than normal to form other medicines. These blood clots, and tend to bleed include medicines bought If you have any concerns from the skin and mucous from pharmacies, about using this medicine, membranes such as the nose, supermarkets and health please talk to your doctor. mouth and intestines. Because food stores. Follow your doctor’s advice VWF provides stability for the have any other medical even if it is different from fragile FVIII protein in the conditions what this leaflet says. blood, patients with VWD may also have low FVIII levels. are pregnant or Please read this leaflet breast-feeding carefully and keep it for Biostate® is also used in patients become pregnant during future reference. with haemophilia A, a bleeding your treatment. disorder, in which there are low The information in this leaflet is levels of FVIII or abnormal If you want further information, subject to change. Please check FVIII. Individuals with low consult your doctor or with your Haemophilia levels or abnormal FVIII have Haemophilia Treatment Centre. Treatment Centre if there is any difficulty in forming blood clots, new information about this with these clots often taking About blood products medicine that you should know longer than normal to be made. since you were last treated. Sometimes the individual may Biostate® is manufactured from bleed unexpectedly into their human plasma (the liquid ® What Biostate is joints, muscles or internal component of blood) collected used for organs. by the Australian Red Cross Blood Service. When products Biostate® contains FVIII and Ask your Haemophilia are made from human blood and VWF in a purified and Treatment Centre if you have injected into you, it is possible concentrated form. Both FVIII any questions about why that viruses or other substances ® and VWF are blood proteins that Biostate has been prescribed could be present in the product for you. and cause an illness. These Biostate AU CMI 23.00 Page 1 of 7 could be viruses such as How to use Biostate® 4. Wash hands with soap and hepatitis, human water, dry with a clean immunodeficiency virus (HIV), The dosage and administration towel. or parvovirus B19 and of Biostate® must be carefully 5. Select an appropriate work theoretically the controlled. Your doctor will be area with good lighting and Creutzfeldt-Jakob Disease responsible for determining a surface which can be (CJD) agent. There could also what dose is appropriate to your cleaned (such as a kitchen be other infectious agents some condition. table). of which may not yet have been ® discovered. Biostate will usually be given 6. Using a clean cloth or paper in a hospital. Should your doctor towel, clean the preparation To reduce the risk of this decide that treatment at home is area with methylated spirits. happening, strict controls are appropriate, your Haemophilia 7. Gather the equipment to be applied when selecting blood Treatment Centre will provide used. donors and donations. In detailed instructions on how to ® addition, extra steps are taken use Biostate . Equipment when manufacturing this ® product. Biostate is specially The following procedures are One carton of Biostate® treated to remove and kill given as a guide only: containing: viruses. This special treatment is ® - one vial of Biostate® considered effective against Preparing Biostate certain viruses known as for administration - one vial of Water for enveloped viruses (such as HIV Injections and hepatitis B and C), and also You will need one 5 mL Water - one Mix2Vial™ filter the non-enveloped virus, for Injections vial for each transfer set. hepatitis A. They may be of 250 IU and 500 IU (100 IU/mL) limited value against non- vial of Biostate®, or one 10 mL Check the expiry date of each enveloped viruses such as Water for Injections vial for item. Do not use if expired. parvovirus B19. Despite these each 500 IU (50 IU/mL) and safety measures, such products 1000 IU vial of Biostate®. two alcohol wipes may still potentially transmit sharps container disease. 1. Ensure you have all the required equipment to waste container for Vaccines are available against administer Biostate®. discarding biological material some of these viruses and your 2. Allow the vials of Biostate® doctor will be able to help you and Water for Injections to plastic syringe(s) decide whether it is worthwhile reach room temperature adhesive tape having any of those vaccines. prior to use, which may take up to one hour. Do not cotton balls Please discuss the risks and warm the Water for benefits of Biostate® with your intravenous injection set Injections in hot water. doctor. gloves. 3. Remove jewellery, watches, rings, etc. Biostate AU CMI 23.00 Page 2 of 7 Instructions for cannula of the Mix2Vial™ Figure 2 ® firmly through the rubber Biostate stopper of the Water for reconstitution Injections vial. See Figure 1, (5 mL Water for Follow these steps to prepare the Injections vial is provided injection. for 250 IU vial and 500 IU (100 IU/mL) vial and 1. Wash hands with soap and 10 mL Water for Injections water, dry with a clean vial is provided for 500 IU towel. (50 IU/mL) vial and ® 2. Ensure Biostate and Water 1000 IU vial). for Injections are at room temperature. 3. Remove flip top caps from Biostate® and Water for Figure 3 Injections vials. 4. Wipe the rubber stoppers of both the Biostate® and Water for Injections vials with the alcohol wipes and allow to dry for two minutes. Do not leave the Figure 1 alcohol wipes resting on the stoppers. Do not touch the rubber stoppers with your fingers. 5. Open the lid of the Mix2Vial™ packaging. If Figure 4 the seal of the lid is not intact or you have any WFI = Water for Injections other concerns about the integrity of the 6. While holding onto the vial ™ Mix2Vial , do not use it of Water for Injections, but return it to your carefully remove the outer Haemophilia Treatment package from the Centre or Australian Red Mix2Vial™, being careful to Cross Blood Service. Place leave the Mix2Vial™ firmly the Water for Injections vial attached to the vial of Water on a level surface and hold for Injections, see Figure 2. the vial firmly. Take the Make sure that you only ™ Mix2Vial together with remove the outer package the outer package, invert it and not the Mix2Vial™. and push the blue plastic Biostate AU CMI 23.00 Page 3 of 7 7. With the Biostate® vial held 8. With the Water for 11. Once the Biostate® has been firmly on a level surface, Injections and Biostate® transferred into the syringe, invert the Water for vials still attached to the firmly hold the barrel of the Injections with the Mix2Vial™, gently swirl (do syringe (keeping the syringe Mix2Vial™ attached and not shake) the Biostate® plunger facing down) and push the transparent plastic vial until all of the product detach the Mix2Vial™ from cannula end of the is dissolved. Ensure the the syringe. Do not use the Mix2Vial™ firmly through contents of the vial are Mix2Vial™ for injection. the stopper of the Biostate® completely dissolved. If a Note: One large syringe vial, see Figure 3. The clot or gel forms do not use may be used to withdraw water will be drawn into the the product but return it to Biostate® from multiple vial by the vacuum your Haemophilia vials. contained within the Treatment Centre or ® Biostate vial. If water is Australian Red Cross Blood 12. Discard the empty vial of not drawn into the vial, it Service. Biostate® with the means that there is no 9. Once the contents of the transparent part of the vacuum in the vial and the ™ Biostate® vial are Mix2Vial attached, into an seal may be faulty. Do not completely dissolved, appropriate waste container. use the product but return firmly hold both the it to your Haemophilia ® transparent and blue parts Use Biostate as soon as you Treatment Centre or the of the Mix2Vial™. Unscrew can after preparation. (Make Australian Red Cross the Mix2Vial™ into two sure it is used for one person Blood Service. separate pieces, see on one occasion only). The Note: The Mix2Vial™ is Figure 4. Discard the solution must not be stored for intended to filter the empty Water for Injections longer than 8 hours and the contents of a single vial of vial with the blue part of the infusion should be completed Biostate® only. If multiple Mix2Vial™ still attached as soon as practicable, as ® vials of Biostate® are to be into an appropriate waste Biostate does not contain an given, a separate container. antimicrobial preservative. Mix2Vial™ must be used Any unused portion remaining 10. While the Biostate® vial is for each vial. in the vial must be discarded upright, attach a plastic appropriately. disposable syringe to the transparent part of the Do not refrigerate Biostate® Mix2Vial™. Invert the once it has been prepared. system and draw the Biostate® into the syringe Injection by pulling the plunger back administration slowly.
Recommended publications
  • CSL Behring Letterhead Template
    AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP MARBURG, Germany — 14 November 2016 CHMP positive opinion moves AFSTYLA one step closer to approval in the European Union AFSTYLA is the first and only single-chain therapy for haemophilia A. The therapy has been specifically designed for greater molecular stability and duration of action through strong affinity to von Willebrand factor (VWF) AFSTYLA has been shown to offer excellent haemostatic efficacy in both prophylaxis and on-demand treatment, and the option of twice weekly dosing with low unit consumption Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A. AFSTYLA, CSL Behring’s novel, recombinant factor VIII therapy for adults and children, is the first and only single-chain product for haemophilia A. It is specifically designed for protection from bleeds with two or three times weekly dosing and low unit consumption at both dosing regimens. In clinical trials, AFSTYLA demonstrated a strong safety profile with no inhibitors observed in previously treated patients undergoing prophylaxis. “For 100 years, CSL has focused on researching and developing innovative therapies that meet the treatment challenges patients face,” said Dr. Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited. “CHMP’s positive opinion for AFSTYLA® moves us one step closer to bringing this novel treatment option to haemophilia A patients in the European Union. Once approved, AFSTYLA will provide adults and children with a therapy that delivers on our promise to develop and bring to market innovative specialty biotherapies that help patients live full lives.” About Haemophilia A Primarily affecting males, haemophilia A is a congenital bleeding disorder characterised by deficient or defective factor VIII.
    [Show full text]
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • (Human) Monoclate-P® Factor VIII: C Pasteurized Monoclonal Antibody Purified
    CSL Behring 1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 Tel 610-878-4000 March 2018 Important availability information for Antihemophilic Factor (Human) Monoclate-P® Factor VIII: C Pasteurized Monoclonal Antibody Purified Dear Valued Customer: Throughout CSL Behring’s long history of providing leading hemophilia treatments, we have offered a broad portfolio of products, including Antihemophilic Factor (Human) Monoclate- P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. We are writing now to keep you updated about product availability. CSL Behring has made the difficult decision to discontinue Monoclate-P and we estimate that supply will be available through December 2018, giving you time to consider your patients’ treatment options. Please note that due to expiration dating, availability of the 1500 IU vial size may be limited. We recognize that Monoclate-P has been an important part of your patients’ lives, and we remain committed to keeping you informed so you can appropriately advise them. We also want to share the rationale behind this decision. As hemophilia A treatment has advanced, and patients have transitioned from plasma-derived to recombinant and longer-acting therapies, it has been increasingly difficult to sustain the production and distribution of Monoclate-P. We encourage your Monoclate-P patients to speak with their physician regarding treatment options. As a patient-focused company, CSL Behring strives to create innovative therapies for the hemophilia community. That’s why we will continue to offer two therapies, AFSTYLA®, Antihemophilic Factor (Recombinant), Single Chain, a next-generation Factor VIII therapy, and plasma-derived Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P®.
    [Show full text]
  • RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------------CONTRAINDICATIONS ------------------------------------ These highlights do not include all the information needed to use RIASTAP • Known anaphylactic or severe systemic reactions to human plasma-derived products (4). safely and effectively. See full prescribing information for RIASTAP. ---------------------------------WARNINGS AND PRECAUTIONS---------------------------- RIASTAP®, Fibrinogen Concentrate (Human) • Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment (5.1). Lyophilized Powder for Solution for Intravenous Injection • Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis (5.2). Initial U.S. Approval: 2009 • Because RIASTAP is made from human blood, it may carry a risk of transmitting ------------------------------------RECENT MAJOR CHANGES--------------------------------- infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent Indications and Usage (1) 06/2021 and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3). Dosage and Administration (2.2) 07/2020 -------------------------------------ADVERSE REACTIONS-------------------------------------- ----------------------------------INDICATIONS AND USAGE----------------------------------- • The most serious adverse reactions observed are thrombotic episodes (pulmonary RIASTAP, Fibrinogen
    [Show full text]
  • 1. NAME of the MEDICINAL PRODUCT Beriplast P Combi-Set 0.5 Ml, 1 Ml, 3 Ml Powders and Solvents for Sealant. 2. QUALITATIVE and Q
    CSL Behring Beriplast P Combi-Set 1. NAME OF THE MEDICINAL PRODUCT Beriplast P Combi-Set 0.5 ml, 1 ml, 3 ml Powders and solvents for sealant. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative composition Combi-Set I: Active substances Human fibrinogen, Coagulation Factor XIII (human), Aprotinin (bovine) Combi-Set II: Active substances Human thrombin, Calcium Chloride Quantitative composition Combi-Set I per 1 ml Vial 1 Fibrinogen Concentrate: total dried substance 174 mg fibrinogen (human plasma protein fraction) 90 mg coagulation factor XIII (human plasma protein fraction) 60 IU Vial 2 Aprotinin Solution: volume 1.0 ml bovine lung aprotinin 1000 KIU* corresponding to 0.56 PEU** * KIU = Kallikrein Inactivator Unit ** PEU = Ph. Eur. Unit (1 PEU ^ 1800 KIU) Combi-Set II per 1 ml Vial 3 Thrombin: total dried substance 7.6 mg with a human plasma protein fraction thrombin activity 500 IU Vial 4 Calcium Chloride Solution: volume 1.0 ml calcium chloride dihydrate 5.9 mg For the full list of excipients, see section 6.1. CSL Behring Beriplast P Combi-Set 3. PHARMACEUTICAL FORM Powders and solvents for sealant. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis (including endoscopic treatment of bleeding gastroduodenal ulcer) as a tissue glue to promote adhesion/sealing or as suture support 4.2 Posology and method of administration The use of Beriplast is restricted to experienced physicians and/or surgeons. Posology The volume of Beriplast to be applied and the frequency of application should always be oriented towards the underlying clinical needs of the patient.
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use IDELVION® Safely and Ef
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------DOSAGE FORMS AND STRENGTHS------------------- These highlights do not include all the information needed to use IDELVION is available as a lyophilized powder in single-use vials containing IDELVION® safely and effectively. See full prescribing information for nominally 250, 500, 1000 or 2000 IU. (3) IDELVION. -------------------------------CONTRAINDICATIONS ----------------------------- IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Do not use in patients who have had life-threatening hypersensitivity reactions Protein] to IDELVION or its components, including hamster proteins. (4) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 2016 ---------------------------WARNINGS AND PRECAUTIONS-------------------- • Hypersensitivity reactions, including anaphylaxis, are possible. Should ----------------------------INDICATIONS AND USAGE--------------------------- symptoms occur, discontinue IDELVION and administer appropriate IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein treatment. (5.1) (rIX-FP), a recombinant human blood coagulation factor, is indicated in • Development of neutralizing antibodies (inhibitors) to IDELVION may children and adults with hemophilia B (congenital Factor IX deficiency) for: occur. If expected Factor IX plasma recovery in patient plasma is not • On-demand control and prevention of bleeding episodes attained, or if bleeding is not controlled with an appropriate dose, perform • Perioperative
    [Show full text]
  • Coding and Reimbursement Guide
    Eligible patients can save up to $12, IDELVION CMS-1500 CLAIM FORM Claim Form Example Important Safety Information IDELVION®, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP), is indicated in children and adults with hemophilia B (congenital Factor IX deficiency) for: • On-demand treatment and control of bleeding episodes • Perioperative management of bleeding • Routine prophylaxis to reduce the frequency of bleeding episodes CALL 1-800-676-4266 IDELVION is not indicated for induction of immune tolerance in patients with hemophilia B. TO SPEAK WITH A CASE MANAGER IDELVION is contraindicated in patients who have had life-threatening hypersensitivity to the product Monday–Friday, 8 AM–8 PM ET or its components, including hamster proteins. Through IDELVION ConnectSM, your patients can find a centralized collection of services, such as financial support, the advocate IDELVION is for intravenous use only. IDELVION can be self-administered or administered by a caregiver with mentorship program, community connections, and additional information on hemophilia B. Look to IDELVION Connect as the training and approval from a healthcare provider or hemophilia treatment center. Higher dose per kilogram source for support as your patients begin and continue their experience with IDELVION. body weight or more frequent dosing may be needed for pediatric patients. Hypersensitivity reactions, including anaphylaxis, are possible. Advise patients who self-administer to IDELVION Advocate Program immediately report symptoms of hypersensitivity, including angioedema, chest tightness, hypotension, A free trial of IDELVION Patients can have one-on-one generalized urticaria, wheezing, and dyspnea. If symptoms occur, discontinue IDELVION and administer Get your patients a one-month trial conversations with advocates about appropriate treatment.
    [Show full text]
  • See Full Prescribing Information for Helixate FS
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------------------CONTRAINDICATIONS---------------------------------------- These highlights do not include all the information needed to use Helixate FS Do not use in patients who have life-threatening hypersensitivity reactions, including ana- safely and effectively. See full prescribing information for Helixate FS. phylaxis to mouse or hamster protein or other constituents of the product (4). ® Helixate FS ------------------------------WARNINGS AND PRECAUTIONS------------------------------- [Antihemophilic Factor (Recombinant), Formulated with Sucrose] • Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, For Intravenous Use, Lyophilized Powder for Reconstitution discontinue treatment with Helixate FS and administer appropriate treatment (5.1). • Development of activity-neutralizing antibodies can occur in patients receiving factor Initial U.S. Approval: 1993 VIII-containing products, including Helixate FS. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform --------------------------------INDICATIONS AND USAGE------------------------------------- an assay that measures factor VIII inhibitor concentration (5.2). Helixate FS is an Antihemophilic Factor (Recombinant) indicated for: • When clotting is normalized by treatment with factor VIII, development of cardiovas- • On-demand treatment and control of bleeding episodes in adults and children with cular risk factors may
    [Show full text]
  • Plasma Protein Products ‐ Product Information August 2018
    Plasma Protein Products ‐ Product Information August 2018 Shipping Max RT Temp for Storage (<25°C) Product & Product Sizes Supplier 24hrs Temp (°C) Storage (°C) Period ** Anti‐Inhibitor Coagulant FEIBA™NF (1000,2500 IU) Shire 2 to 25 2 to 25 Labelled Date Plasbumin®5% (50mL, 250mL) Grifols 2 to 30 2 to 30 Labelled Date Albumin 25%/Plasbumin® (100mL,250mL) Grifols/CBS 2 to 30 2 to 30 Labelled Date Albumin Alburex®5% (250mL, 500mL) 2 to 30 2 to 30 Labelled Date CSL Berhing Alburex®25% (50mL, 100mL) 2 to 30 2 to 30 Labelled Date Antithrombin III Antithrombin III NF (1000 IU) Shire 2 to 82 to 8 N/A Berinert® (500,1500 IU) CSL Berhing 2 to 25 2 to 25 Labelled Date C1 Inhibitor CINRYZE® (500 IU) Shire 2 to 25 2 to 25 Labelled Date Factor VII *Factor VII (600 IU) Shire 2 to 82 to 8 N/A Recombinate Factor VIIa (rFVIIa) NiaStase RT® (1.0mg,2.0mg,5.0mg) Novo Nordisk 2 to 25 2 to 25 Labelled Date *Hemofil M NF (1000 IU) Shire 2 to 30 2 to 30 Labelled Date Factor VIII *Koate‐DVI (500,1000 IU) Grifols 1 to 25 2 to 86 months Kovaltry FS (250, 500, 1000, 2000, 3000 IU) Bayer 2 to 25 2 to 812 months Pfizer Canada Recombinate Factor VIII Xyntha® (250, 500, 1000, 2000,3000 IU) Inc 2 to 82 to 8 3 months (>8C) Eloctate™ (250, 500, 750, 1000, 1500, 2000, 3000 IU) Bioverativ 2 to 82 to 86 months Nuwiq (250, 500, 1000, 2000,3000,4000 IU) Octapharma 2 to 82 to 812 months Shipping Max RT Temp for Storage (<25°C) Product & Product Sizes Supplier 24hrs Temp (°C) Storage (°C) Period ** Factor VIII/von Willebrand Humate P® (1000 RcoF, 2000 RcoF IU) CSL Behring 2
    [Show full text]
  • Sufficient Thrombin Generation Despite 95% Hemodilution: an in Vitro Experimental Study
    Journal of Clinical Medicine Article Sufficient Thrombin Generation Despite 95% Hemodilution: An In Vitro Experimental Study Johannes Gratz 1 , Christoph J. Schlimp 2,3, Markus Honickel 4, Nadine Hochhausen 4 , Herbert Schöchl 2,5 and Oliver Grottke 4,* 1 Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Waehringer Guertel 18–20, 1090 Vienna, Austria; [email protected] 2 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Centre, Donaueschingenstraße 13, 1200 Vienna, Austria; [email protected] (C.J.S.); [email protected] (H.S.) 3 Department of Anesthesiology and Intensive Care Medicine, AUVA Trauma Centre Linz, Garnisonstrasse 7, 4010 Linz, Austria 4 Department of Anesthesiology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; [email protected] (M.H.); [email protected] (N.H.) 5 Department of Anaesthesia and Intensive Care Medicine, AUVA Trauma Centre Salzburg, Academic Teaching Hospital of the Paracelsus Medical University Salzburg, Doktor-Franz-Rehrl-Platz 5, 5010 Salzburg, Austria * Correspondence: [email protected]; Tel.: +49-241-80-80972 Received: 27 October 2020; Accepted: 24 November 2020; Published: 25 November 2020 Abstract: Guidelines for the treatment of severe bleeding comprise viscoelastic-test-guided use of coagulation factor concentrates as part of their recommendations. The aim of this study is to investigate the effects of substituting fibrinogen, prothrombin complex concentrate, and a combination of both on conventional coagulation tests, viscoelastic test results, and thrombin generation. Blood was drawn from seven healthy volunteers to obtain platelet-free plasma, which later was diluted by replacing 40%, 60%, 80%, 90%, 95%, and 99% with a crystalloid solution.
    [Show full text]
  • Humate-P Diagnostic Codes
    12/4/2017 Humate-P® United States Home > US Products > Humate-P® Humate-P ® Antihemophilic Factor/von Willebrand Factor Complex (Human) Full Prescribing Information for Humate-P® Important Safety Information Humate-P is an Antihemophilic Factor/von Willebrand Factor (VWF) Complex (Human) indicated for: Hemophilia A — Treatment and prevention of bleeding in adults (1.1). Von Willebrand disease (VWD) — in adults and pediatric patients in the (1) Treatment of spontaneous and trauma-induced bleeding episodes, and (2) Prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD where the use of desmospressin is known or suspected to be inadequate (1.2). Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes in VWD. Visit www.humate-p.com to learn more. Diagnostic Codes (ICD-10-CM) ICD-10-CM Codes Used to identify patient medical conditions (for claims with a date of service on or after October 1, 2015) Code Description D66 Hereditary factor VIII deficiency D68.0 von Willebrand's Disease 30233V1 Transfusion of Nonautologous Antihemophilic factors into peripheral vein, percutaneous approach 30243V1 Transfusion of Nonautologous antihemophilic factors into central vein, percutaneous approach Billing Codes (HCPCS, NDC, CPT) HCPCS Codes The following HCPCS codes describe supplies (including drugs) rendered by the billing provider. CMS publishes and maintains the HCPCS code set. These codes are entered to paper claim form CMS-1500 in Field 24; or, to electronic claim form ASC 837P in Loop 2400, Segment SV101-2, with the Qualifier "HC" entered to Segment SV101-1, unless otherwise directed by the payor.
    [Show full text]
  • Product Labeling
    CSL Behring Prothrombin Complex Concentrate (Human), Kcentra™ 1.14.1.3 Draft Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------DOSAGE FORMS AND STRENGTHS------------------- These highlights do not include all the information needed to use • Kcentra is available as a single-use vial containing coagulation Factors II, KCENTRA safely and effectively. See full prescribing information for VII, IX and X, and antithrombotic Proteins C and S as a lyophilized KCENTRA. concentrate. (3) KCENTRA (Prothrombin Complex Concentrate (Human)) -------------------------------CONTRAINDICATIONS ----------------------------- For Intravenous Use, Lyophilized Powder for Reconstitution Kcentra is contraindicated in patients with: Initial U.S. Approval: 2013 • Known anaphylactic or severe systemic reactions to Kcentra or any components in Kcentra including heparin, Factors II, VII, IX, X, Proteins C WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC and S, Antithrombin III and Human albumin. (4) COMPLICATIONS • Disseminated intravascular coagulation. (4) Patients being treated with Vitamin K antagonists (VKA) therapy have • Known heparin-induced thrombocytopenia. Kcentra contains heparin. (4) underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the ---------------------------WARNINGS AND PRECAUTIONS-------------------- potential risks of thromboembolic events, especially in patients with the • Hypersensitivity reactions may occur. If necessary, discontinue history
    [Show full text]